JSC
ABCL icon

Jackson Square Capital’s AbCellera Biologics ABCL Stock Holding History

Jackson Square Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,230
Closed -$46.3K – 127
2024
Q1 		$46.3K Buy
+10,230
New +$52.2K 0.01% 137

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Jackson Square Capital's ABCL Position: Q2 2024 in Review

Jackson Square Capital sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 10,230 shares — an estimated $46.3K sold.

Jackson Square Capital first reported a position in ABCL in Q1 2024 and held it in 1 quarter. The position peaked at $46.3K in Q1 2024. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Jackson Square Capital reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Jackson Square Capital sold 10,230 AbCellera Biologics shares in Q2 2024, an estimated $46.3K.
  • Jackson Square Capital first reported a position in AbCellera Biologics in Q1 2024 and held it in 1 quarter.
  • Jackson Square Capital's AbCellera Biologics position peaked at $46.3K in Q1 2024.
  • 147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Jackson Square Capital's 13F filing for Q2 2024, filed 5 Aug 2024.